Rearming the body’s immune system to fight cancer

We’re developing more precise and more accessible treatment alternatives for patients with solid cancers

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.

Learn more about us

Some of our partners

Latest news

Importance of building Australia-China biotech collaborations

By Karen Loudon / November 1, 2023
China is Australia’s greatest two-way trading partner in products and services, making up close to one-third of the nation's international...
Read More

Life Science Success podcast with Prof. Alan Trounson

By Karen Loudon / October 20, 2023
Cartherics’ CEO, Prof. Alan Trounson, was recently a guest on Life Science Success podcast. Hosted by Dr Don Davies, this...
Read More

Cartherics appoints new Chief Scientific Officer

By Karen Loudon / October 17, 2023
Melbourne, Australia, 17 October 2023 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for...
Read More